Ascendis Pharma (ASND) Stock Overview
Operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ASND Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ascendis Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$261.23 |
| 52 Week High | US$282.15 |
| 52 Week Low | US$203.80 |
| Beta | 0 |
| 1 Month Change | 2.62% |
| 3 Month Change | 19.80% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 6.46% |
Recent News & Updates
Recent updates
ASND: Yuviwel Settlement And Q2 TransCon Execution Will Test Fairly Priced Story
Analysts have nudged their price targets higher for Ascendis Pharma, with a modest move in fair value from about $260 to $269 as they factor in the Yuviwel royalty settlement with BioMarin and updated assumptions for future royalties and earnings, even as they temper revenue growth, profit margin, and future P/E expectations in their models. Analyst Commentary Recent Street research on Ascendis Pharma shows a mixed but generally constructive tone.
ASND: TransCon Platform Execution And Q2 Progress Should Drive Future Upside
Analysts have modestly raised their Ascendis Pharma price target to $313 from $305, citing fresh coverage and updated models that focus on the TransCon platform's three FDA approvals, Yorvipath's commercial ramp, Yuviwel's achondroplasia launch, and renewed interest in rare endocrine disease stocks. Analyst Commentary Recent Street research on Ascendis Pharma clusters around the company’s execution on its TransCon platform and the commercial progress of Yorvipath and Yuviwel.Ascendis Pharma A/S Just Recorded A 104% EPS Beat: Here's What Analysts Are Forecasting Next
Ascendis Pharma A/S ( NASDAQ:ASND ) just released its latest second-quarter results and things are looking bullish. It...ASND: Q2 Execution And M&A Interest Will Test Fairly Priced Story
Analysts have increased their price target for Ascendis Pharma, with the updated fair value estimate moving by about $11 to $259.95. This change reflects recent target hikes around Q2 earnings previews and a growing focus on the company's execution and potential M&A interest.ASND: Rare Endocrine Execution And Q2 Earnings Should Drive Future Upside
Analysts have lifted the Ascendis Pharma fair value estimate from $293.79 to $304.60, citing updated assumptions around revenue growth, profit margins, and sector-wide price target increases that reflect greater focus on company-specific execution. Analyst Commentary Recent Street research around Ascendis Pharma points to a generally constructive outlook on the stock, with several firms adjusting price targets higher and highlighting upcoming earnings as an important test of execution.ASND: M&A Hype And Launch Expectations Will Test Lofty Share Price
Analysts have nudged their fair value estimate for Ascendis Pharma lower from $254.97 to $248.54, reflecting updated assumptions around revenue growth, profit margins, and future P/E. The revision still coincides with higher Street price targets supported by recent research highlighting potential M&A interest and product launch traction.Ascendis Pharma: Behind The Stock Surge
Summary Ascendis Pharma has more than tripled over the past two and a half years, driven by Yorvipath's blockbuster launch and Yuviwel's FDA approval. Yorvipath's rapid adoption and ongoing label expansion underpin robust revenue growth. Yuviwel-Skytrofa combo therapy demonstrated unprecedented efficacy in achondroplasia, positioning ASND ahead of competitors pending pivotal trials. Patent litigation is one risk with the stock. An analysis around Ascendis Pharma follows in the paragraphs below. Read the full article on Seeking AlphaASND: Rare Endocrine Portfolio Progress Will Drive Future Upside Potential
The analyst price target for Ascendis Pharma has moved from $342.08 to $293.79 as analysts adjust their models to reflect updated assumptions on long term growth, margins and P/E expectations, alongside recent Street research that highlights confidence in Yorvipath and ongoing target revisions. Analyst Commentary Street research on Ascendis Pharma has recently centered on Yorvipath's commercial progress, updated growth assumptions and how these feed into valuation targets and execution risk.Statutory Earnings May Not Be The Best Way To Understand Ascendis Pharma's (NASDAQ:ASND) True Position
We didn't see Ascendis Pharma A/S' ( NASDAQ:ASND ) stock surge when it reported robust earnings recently. We think that...Long Term TransCon Pipeline Execution Will Shape Future Cash Flows And Business Durability
Catalysts About Ascendis Pharma Ascendis Pharma focuses on developing and commercializing long-acting therapies for rare endocrine and growth disorders using its TransCon technology platform. What are the underlying business or industry changes driving this perspective?Long Acting TransCon Therapies Will Reshape Rare Endocrine Treatment Over The Coming Years
Catalysts About Ascendis Pharma Ascendis Pharma focuses on developing and commercializing long acting therapies for rare endocrine and growth disorders using its TransCon technology platform. What are the underlying business or industry changes driving this perspective?Shareholder Returns
| ASND | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.6% | -4.4% | -0.2% |
| 1Y | n/a | 39.9% | 14.8% |
Return vs Industry: Insufficient data to determine how ASND performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ASND performed against the US Market.
Price Volatility
| ASND volatility | |
|---|---|
| ASND Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ASND has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ASND's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 1,189 | Jan Mikkelsen | ascendispharma.com |
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Ascendis Pharma A/S Fundamentals Summary
| ASND fundamental statistics | |
|---|---|
| Market cap | US$17.13b |
| Earnings (TTM) | US$861.31m |
| Revenue (TTM) | US$1.22b |
Is ASND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASND income statement (TTM) | |
|---|---|
| Revenue | €1.05b |
| Cost of Revenue | €91.13m |
| Gross Profit | €955.90m |
| Other Expenses | €214.14m |
| Earnings | €741.76m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 11.29 |
| Gross Margin | 91.30% |
| Net Profit Margin | 70.84% |
| Debt/Equity Ratio | 21.0% |
How did ASND perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 23:26 |
| End of Day Share Price | 2026/09/10 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ascendis Pharma A/S is covered by 31 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eliana Merle | Barclays |
| Tazeen Ahmad | BofA Global Research |
| Michelle Gilson | Canaccord Genuity |